Introduction {#S1}
============

Liver cirrhosis is a chronic, diffuse, progressive, degenerative disease that ends with liver parenchymal damage. Histologically, the lobules are structurally altered with dense peri-lobular connective tissue formation and often areas of regeneration develop. These areas of regeneration are described as cirrhotic nodules and they have a reduced blood supply resulting in impaired liver functions \[[@ref1], [@ref2]\].

Sleep-disordered breathing (SDB) is an umbrella term used to describe a number of disorders. These include abnormalities in the frequency, pattern, upper airway resistance and/or depth of breathing during sleep. It has been considered as a global health problem, because epidemiological studies have shown SDB to affect as many as 2% to 9% of middle-aged adults and more than 15% of older adults \[[@ref3]\].

The most common SDB pattern is obstructive sleep apnea (OSA)/hypopnea syndrome. In addition, the following disorders are included under the term SDB syndromes: obesity hypoventilation syndrome (OHS), central sleep apnea (CSA), Cheyenne-Stokes respiration (CSR) and upper airway resistance syndrome (UARS) \[[@ref4]\].

Obstructive sleep apnea is characterized by frequent episodes of upper airway collapse during sleep time resulting in reduction of blood oxygen saturation and usually terminated by arousals from sleep. Most patients awaken in the morning feeling tired and unrefreshed regardless of the duration of their time in bed \[[@ref5]\].

In fact, the association between liver cirrhosis and breathing disorders has long been observed, e.g., sleep apnea is noted in ascetic patients. Moreover, the apnea hypopnea index (AHI) tends to increase with the increase in the amount of ascites. And the authors of one study concluded that a relationship exists between ascites and obstruction of the respiratory tract, especially during sleep \[[@ref6]\].

This study aimed to estimate the prevalence of sleep-disordered breathing among Egyptian cirrhotic adults of viral etiology.

Material and methods {#S2}
====================

This multicenter cross sectional study was carried out in the Tropical Medicine Department and the sleep-disordered breathing unit of the Chest Department, Zagazig University Hospitals, Egypt and Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, Kafrelshiekh University, Egypt in the period from October 2017 to June 2019. The study was approved by the ethical committee board of Zagazig University in July 2017, and written, informed consent was obtained from each patient included in the study. Diagnosis of cirrhosis in the current study was achieved by clinical, biochemical and ultrasonography characteristics.

The study included 64 participants divided as follows:

-- case group (group I, *n* = 48): patients with cirrhosis of viral etiology (43 cases were hepatitis C virus \[HCV\] and 5 were hepatitis B virus \[HBV\]);-- control group (group II, *n* = 16): 16 apparently healthy individuals.

Inclusion criteria: All cirrhotic adults (\> 18 years old) who presented to the hepatology outpatient clinics of the participating centers were offered to participate in the study.

Exclusion criteria: Patients with the following medical problems were excluded from the current study: patients with overt hepatic encephalopathy, cerebrovascular stroke and those with substance abuse disorders, chronic chest diseases, e.g. chronic obstructive pulmonary disease (COPD), pleural effusion, non-viral cirrhosis, renal impairment or renal medical disease, recent gastrointestinal (GIT) bleeding, spontaneous bacterial peritonitis (SBP), hypothyroidism and patients with malignancies.

All participants were subjected to:

Complete history taking with special stress on: past history of hepatic encephalopathy (HE);respiratory symptoms suggestive of chest diseases, e.g. COPD;history of drug intake and particular habits, e.g. smoking, alcohol intake;sleep disturbance symptoms (excessive daytime sleepiness, insomnia at night, tiredness, difficulty waking up, snoring, choking, sleep walking, sleep talking and observed apnea. Sleep disturbance in this study was assessed by the followings: -- Epworth Sleepiness Scale (ESS) questionnaire: Used for evaluation of symptoms of excessive sleepiness. There are eight questions, each question taking scores of 0 to 3. This scale evaluates the chance of dozing off or falling asleep in some situations. 0 = would never doze, 1 = slight chance of dozing, 2 = moderate chance of dozing and 3 = high chance of dozing. It is considered reliable if the patient's score is higher than 10 \[[@ref3]\];-- Berlin Questionnaire: Used to evaluate sleep apnea in the patients. It contains 10 questions about risk factors of sleep apnea such as snoring, day time sleepiness, fatigue, obesity and hypertension \[[@ref7]\].Thorough physical examination including: general and local (abdominal and chest) examination;body mass index (BMI) assessment (weight in kg/height m\<sup\>2\</sup\>).Laboratory investigations: complete blood count (CBC), liver function tests, kidney function tests, prothrombin time, international normalized ratio (INR), random blood sugar (RBS),viral markers (HCVab, HBVsAg),thyroid function tests (thyroid-stimulating hormone -- TSH, free T3, and free T4),arterial blood gases (ABG) analysis.Electrocardiography (ECG).Imaging investigations: Abdominal ultrasonography and plain chest x-ray (postero-anterior view).Polysomnography (PSG): A full-night polysomnographic sleep study was done using SOMNO screen plus (manufactured in Germany) in all patients. PSG is a comprehensive recording of the biophysiological changes that occur during sleep. It included electroencephalography (EEG), electro-oculography (EOG), electrocardiography (ECG), submental and anterior tibial electromyography (EMG), respiratory effort (abdominal and thoracic effort), nasal and oral airflow sensors and pulse oximetry for oxygen saturation. The PSG monitors many body functions including brain (EEG), eye movements (EOG), muscle activity or skeletal muscle activation (EMG) and heart rhythm (ECG) during sleep \[[@ref8]\].

Statistical analysis {#S3}
====================

All data were collected, tabulated and statistically analyzed using SPSS 20.0 for Windows (IBM Corp., Armonk, NY, USA) and MedCalc 13 for Windows (MedCalc Software bvba, Ostend, Belgium). Quantitative data were expressed as the mean ± SD and median (range), and qualitative data were expressed as absolute frequencies (number) and relative frequencies (percentage). Continuous variables were checked for normality using the Shapiro-Wilk test. Independent samples Student's *t*-test was used to compare two groups of normally distributed variables while the Mann-Whitney *U* test was used for non-normally distributed variables. The one-way ANOVA test was used to compare more than two groups of normally distributed variables while the Kruskal-Wallis H test was used for non-normally distributed variables. All tests were two sided and a *p*-value \< 0.05 was considered statistically significant.

Results {#S4}
=======

Study populations {#S4_1}
-----------------

This study included 64 participants: 48 with post-viral cirrhosis (43 HCV and 5 were HBV) compared to 16 apparently healthy controls. There were no statistically significant differences among patients and controls regarding age, sex and BMI ([Table 1](#T1){ref-type="table"}).

###### 

Demographic and clinical data of patients and controls

  ----------------------------------------------------------------------------------------------------------------------------------
  Demographic\                 Control\                            Cirrhotic\   Test          *P*-value\                    
  and clinical data            (*n* = 16)                          (*n* = 48)                 (Sig.)                        
  ---------------------------- ---------------- ------------------ ------------ ------------- ------------ ------- -------- --------
  Sex                                                                                                                       

                               Male             12                 75%                        27           56.2%   1.772§   0.183\
                                                                                                                            (NS)

                               Female           4                  25%                        21           43.8%            

  Age (years)                                                                                                               

                               Mean ± SD        46.18 ±8.30                     49.39 ±6.76   1.55         0.12\            
                                                                                                           (NS)             

                               Median (range)   45.50 (30-58)                   50 (37-62)                                  

  BMI (kg/m\<sup\>2\</sup\>)                                                                                                

                               Mean ± SD        23.25 ±3.28                     25.42 ±4.81   1.67         0.09\            
                                                                                                           (NS)             

                               Median (range)   21.75 (17.50-29)                24 (17-34)                                  

                               Underweight      2                  12.5%                      3            6.2%    4.091§   0.252\
                                                                                                                            (NS)

                               Normal weight    10                 62.5%                      22           45.8%            

                               Overweight       4                  25%                        15           31.2%            

                               Obese I          0                  0%                         8            16.7%            
  ----------------------------------------------------------------------------------------------------------------------------------

Chi-square test, p \< 0.05 is significant, Sig. -- significance, NS -- non-significant

Laboratory parameters {#S4_2}
---------------------

It is observed from the data shown in [Table 2](#T2){ref-type="table"} that cirrhotic patients had derangements in their hepatic synthetic and excretory functions when compared with healthy individuals, and there were significant differences in the levels of serum albumin, INR, and serum bilirubin between the two groups.

###### 

Comparison between control and cirrhotic groups regarding biochemical parameters

  -----------------------------------------------------------------------------------------------------------------------------------
  Complete blood picture                  Control\         Cirrhotic\            Test               *P*-value\               
                                          (*n* = 16)       (*n* = 48)                               (Sig.)                   
  --------------------------------------- ---------------- --------------------- ------------------ ------------ ----------- --------
  Hb (g/dl)                                                                                                                  

                                          Mean ± SD        13.72 ±1.40           10.06 ±2.07        6.547\*      \< 0.001\   
                                                                                                                 (HS)        

                                          Median (range)   13.90 (10.80-15.40)   10 (5-14)                                   

  Platelet count (× 10^3^/ul)                                                                                                

                                          Mean ± SD        283.50 ±91.37         112.70 ±77.39      --5.078^•^   \< 0.001\   
                                                                                                                 (HS)        

                                          Median (range)   270 (170-440)         102 (14-386)                                

  Liver functions and blood gases                                                                                            

  Total serum bilirubin (0.3-1.2 mg/dl)                                                                                      

                                          Mean ± SD        0.98 ±0.11            2.70 ±1.54         --4.412^•^   \< 0.001\   
                                                                                                                 (HS)        

                                          Median (range)   1 (0.70-1.20)         2.65 (0.40-6.40)                            

  Albumin (3.5-5 g/dl)                                                                                                       

                                          Mean ± SD        4.18 ±0.39            2.83 ±0.54         9.087\*      \< 0.001\   
                                                                                                                 (HS)        

                                          Median (range)   4.05 (3.70-5)         2.85 (1.60-4)                               

  AST (5-40 u/l)                                                                                                             

                                          Mean ± SD        31.81 ±4.18           59.72 ±57.38       --2.924^•^   0.003\      
                                                                                                                 (S)         

                                          Median (range)   32 (25-38)            48 (15-304)                                 

  ALT (5-35 u/l)                                                                                                             

                                          Mean ± SD        32.18 ±3.72           33.25 ±17.96       --0.365^•^   0.715\      
                                                                                                                 (NS)        

                                          Median (range)   32 (25-39)            32 (11-111)                                 

  INR                                                                                                                        

                                          Mean ± SD        0.98 ±0.04            1.39 ±0.33         --5.401^•^   \< 0.001\   
                                                                                                                 (HS)        

                                          Median (range)   1 (0.90-1)            1.30 (0.90-2.40)                            

  pH                                                                                                                         

                                          Mean ± SD        7.39 ±0.04            7.41 ±0.06         --0.984^•^   0.325\      
                                                                                                                 (NS)        

                                          Median (range)   7.40 (7.35-7.45)      7.40 (7.35-7.57)                            

  Normal                                  16               100%                  39                 81.2%        3.491§      0.097\
                                                                                                                             (NS)

  Respiratory alkalosis                   0                0%                    9                  18.8%                    

  PaO~2~ (mmHg)                                                                                                              

                                          Mean ± SD        95.56 ±1.36           85.18 ±7.69        --5.080^•^   \< 0.001\   
                                                                                                                 (HS)        

                                          Median (range)   95 (94-98)            86.50 (70-97)                               
  -----------------------------------------------------------------------------------------------------------------------------------

Independent samples Student's t-test, •Mann-Whitney U test, p \< 0.05 is significant, Sig. -- significance, S -- significant, NS -- non-significant, HS -- highly significant

Regarding blood oxygen (O~2~) parameters, it is obvious that cirrhotic patients had lower PaO~2~ in their ABG compared to the normal individuals (*p* \< 0.001).

Characteristics of the cirrhotic group {#S4_3}
--------------------------------------

Characteristics of the cirrhotic group are shown in [Table 3](#T3){ref-type="table"}. The cirrhotic cohort comprised 48 patients, 16 in each Child class. It is clear that Child score and degree of ascites were higher in the advanced stage of liver cirrhosis. All patients with Child A cirrhosis were treated with direct acting antiviral therapy according to the guidelines of the Egyptian National committee for prevention and control of viral hepatitis (sofosbuvir + daclatasvir + ribavirin), while patients with Child B and C cirrhosis were not treated per the same protocol during the period of the study. The five patients with HBV infection all had HBeAg negative hepatitis and all were under treatment with entecavir.

###### 

Demographic and clinical data of the cirrhotic group

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Demographic\                 Cirrhotic patients   Test                  *P*-value\                                                                                         
  and clinical data                                                       (Sig.)                                                                                             
  ---------------------------- -------------------- --------------------- ------------ ------------------ ---- ----------------- ----------- ----------- ------- ----------- -----------
  Sex                                                                                                                                                                        

                               Male                 9                     56.2%                           10   62.5%                         8           50%     0.508^§^    0.776\
                                                                                                                                                                             (NS)

                               Female               7                     43.8%                           6    37.5%                         8           50%                 

  Age (years)                                                                                                                                                                

                               Mean ± SD            48.68 ±6.37                        48.60 ±7.36             50.81 ±6.73       0.515\*     0.601\                          
                                                                                                                                             (NS)                            

                               Median (range)       49.50 (37-58)                      47.50 (37-62)           52.50 (38-60)                                                 

  BMI (kg/m\<sup\>2\</sup\>)                                                                                                                                                 

                               Mean ± SD            25.97 ±4.65                        24.35 ±4.50             25.94 ±5.36       0.586\*     0.561\                          
                                                                                                                                             (NS)                            

                               Median (range)       24.50 (18.50-33.50)                23.50 (17.90-32)        27.75(17.80-34)                                               

                               Underweight          0                     0%                              1    6.2%                          2           12.5%   4.932^§^    0.553\
                                                                                                                                                                             (NS)

                               Normal weight        8                     50%                             9    56.2%                         5           31.2%               

                               Overweight           5                     31.2%                           5    31.2%                         5           31.2%               

                               Obese I              3                     18.8%                           1    6.2%                          4           25%                 

  Ascites                                                                                                                                                                    

                               No ascites           14                    87.5%                           4    25%                           0           0%      39.877^§^   \< 0.001\
                                                                                                                                                                             (HS)

                               Mild ascites         2                     12.5%                           5    31.2%                         1           6.2%                

                               Moderate ascites     0                     0%                              7    43.8%                         10          62.5%               

                               Marked ascites       0                     0%                              0    0%                            5           31.2%               

  Child score                                                                                                                                                                

                               Mean ± SD            5.56 ±0.51                         7.87 ±0.88              11.12 ±0.80       42.700^•^   \< 0.001\                       
                                                                                                                                             (HS)                            

                               Median (range)       6 (5-6)                            8 (7-9)                 11 (10-13)                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

One-way ANOVA test, *^•^*Kruskal-Wallis H test, ^§^Chi-square test, p \< 0.05 is significant, Sig. -- significance, HS -- highly significant, NS -- non-significant

Sleep-disordered breathing {#S4_4}
--------------------------

The primary end point of the current study was to describe how frequent SDB is among post-viral cirrhotic adults. In this study cirrhotic patients had a higher prevalence rate of SDB compared to healthy controls and the difference was statistically significant ([Table 4](#T4){ref-type="table"}). There was a significant difference between cirrhotic and control groups as regard excessive daytime sleepiness evaluated by the Epworth Sleepiness Scale questionnaire (33.3% of cirrhotic patients experienced excessive daytime sleepiness (EDS) compared to 0% of the healthy controls, *p* = 0.007).

###### 

Comparison between control and cirrhotic groups regarding sleep disturbance

  -------------------------------------------------------------------------------------------------------------------------------------------
  Sleep disturbance              Control\                      Cirrhotic\   Test         *P*-value\                              
                                 (*n* = 16)                    (*n* = 48)                (Sig.)                                  
  ------------------------------ ---------------- ------------ ------------ ------------ ------------ --------------- ---------- ------------
  Excessive daytime sleepiness                                                                                                   

                                 Absent           16           100%                      32           66.7%           7.111^§^   0.007 (S)

                                 Present          0            0%                        16           33.3%                      

  Excessive daytime sleepiness                                                                                                   

                                 Mean ± SD        0.62 ±0.88                7.14 ±5.37   --4.861^•^   \< 0.001 (HS)              

                                 Median (range)   0 (0-3)                   6 (0-19)                                             

  Berlin Questionnaire                                                                                                           

                                 Mean ± SD        0.25 ±0.57                0.75 ±1      --1.938^•^   0.053 (NS)                 

                                 Median (Range)   0 (0-2)                   0 (0-3)                                              

                                 Total score 0    13           81.2%                     26           54.2%           4.267^§^   0.234 (NS)

                                 Total score 1    2            12.5%                     13           27.1%                      

                                 Total score 2    1            6.2%                      4            8.3%                       

                                 Total score 3    0            0%                        5            10.4%                      

  Sleep apnea risk                                                                                                               

                                 No risk          13           81.2%                     26           54.2%           3.733^§^   0.155\
                                                                                                                                 (NS)

                                 Low risk         2            12.5%                     13           27.1%                      

                                 High risk        1            6.2%                      9            18.8%                      
  -------------------------------------------------------------------------------------------------------------------------------------------

*^•^*Mann-Whitney U test, ^§^Chi-square test, p \< 0.05 is significant, Sig. -- significance, S -- significant, NS -- non-significant, HS -- highly significant

From the data obtained by polysomnography it is clear that cirrhotic patients had a significantly (*p* = 0.002) higher rate of SDB (56.2%) in comparison to healthy controls (12.5%). The most frequently encountered SDB patterns among cirrhotics were OSA and AHI. Moreover, the severity of SDB among cirrhotics was significantly higher (*p* = 0.018) than among healthy controls; 25% of cirrhotic patients had mild OSA, 16.6% had moderate OSA and 14.6% had severe OSA, while all the 12.5% of the healthy controls had mild OSA. Of note, there were no significant differences between control and cirrhotic groups as regard sleep efficacy and base SpO~2~ ([Table 5](#T5){ref-type="table"}).

###### 

Comparison between control and cirrhotic groups regarding polysomnography

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Polysomnography                 Control\                            Cirrhotic\   Test                  *P*-value\                        
                                  (*n* = 16)                          (*n* = 48)                         (Sig.)                            
  ------------------------------- ---------------- ------------------ ------------ --------------------- ------------ -------- ----------- --------
  Sleep-disordered breathing                                                                                                               

                                  Absent           14                 87.5%                              21           43.8%    9.269^§^    0.002\
                                                                                                                                           (S)

                                  Present          2                  12.5%                              27           56.2%                

  Obstructive sleep apnea (OSA)                                                                                                            

                                  No OSA           14                 87.5%                              21           43.8%    10.057^§^   0.018\
                                                                                                                                           (S)

                                  Mild OSA         2                  12.5%                              12           25%                  

                                  Moderate OSA     0                  0%                                 8            16.6%                

                                  Severe OSA       0                  0%                                 7            14.6%                

  Apnea hypopnea index (AHI)                                                                                                               

                                  Mean ± SD        3.08 ±1.87                      11.73 ±11.36          --3.001^•^   0.003\               
                                                                                                                      (S)                  

                                  Median (range)   2.75 (1.10-7.90)                7.50 (1.30-36.10)                                       

  Sleep efficacy (%)                                                                                                                       

                                  Mean ± SD        85.39 ±10.44                    85.08 ±11.55          --0.163^•^   0.871\               
                                                                                                                      (NS)                 

                                  Median (range)   88.90 (54.90-97)                88.90 (56.80-99.10)                                     

  Base SpO~2~ (%)                                                                                                                          

                                  Mean ± SD        96.06 ±3.53                     94.77 ±3.35           --1.600^•^   0.110\               
                                                                                                                      (NS)                 

                                  Median (range)   97.50 (88-99)                   95.50 (85-99)                                           

  Minimum SpO~2~ (%)                                                                                                                       

                                  Mean ± SD        90 ±6.77                        84.75 ±10.05          --2.256^•^   0.024\               
                                                                                                                      (S)                  

                                  Median (range)   91 (70-96)                      89 (53-97)                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------

*^•^*Mann-Whitney U test, ^§^Chi-square test, p \< 0.05 is significant, Sig. -- significance, S -- significant, NS -- non-significant

Discussion {#S5}
==========

This study investigates an underestimated problem among cirrhotic patients, i.e. sleep-disordered breathing, and to the best of our knowledge, it is the first of its kind among Egyptian cirrhotic patients despite the high prevalence rates of liver cirrhosis.

In the current study the baseline demographics (age, sex and BMI) were comparable between cirrhotic and control groups ([Table 1](#T1){ref-type="table"}), eliminating their possible contribution to the prevalence of SDB among cirrhotics. Because obesity in particular is a major risk factor for SDB \[[@ref9]\]. The most frequently reported patterns of SDB among our cohort were OSA and AHI, and this is consistent with most of the reports in the literature \[[@ref10]\].

There were significant differences between the control and cirrhotic groups as regard excessive daytime sleepiness evaluated by the ESS questionnaire (33.3% of cirrhotic patients experienced excessive daytime sleepiness compared to none of the healthy control) ([Table 4](#T4){ref-type="table"}). Actually, the data obtained from the questionnaire were reemphasized by polysomnography where 56.2% of cirrhotics significantly had SDB in comparison to 12.5% of healthy controls. This agrees with Al Enezi *et al*. \[[@ref10]\], who found that 29.5% of patients with cirrhosis had EDS. In fact, different studies have reported variable prevalence rates of EDS among cirrhotics ranging from 18.5% to 38% \[[@ref11]-[@ref13]\]. It is logical that the prevalence rates of SBD differ with the methods used in assessment. Subjective tools, such as questionnaires, e.g. ESS and Berlin questionnaires, can be used to collect information on sleep quality and daytime complaints while objective methods such as PSG allow more precise assessment \[[@ref14]\], and this was obvious in the current study; by questionnaire SBD is 33.3% while by PSG the prevalence is higher at 56.2%. This is due to the fact that patients, especially insomniacs, tend to underestimate their sleep quality. Therefore, it seems essential to rely on both subjective and objective methods to obtain a global picture of sleep among the patients \[[@ref15]\].

In the current study not only the frequency but also the severity of SDB were significantly higher in cirrhotic patients compared to controls. We found that 25% of cirrhotic patients had mild OSA, 16.6% had moderate OSA and 14.6% had severe OSA, while 12.5% of healthy controls had mild OSA. This agrees with Al Enezi *et al*. \[[@ref10]\], who found that patients with cirrhosis frequently have high risk of OSA especially among cirrhotic patients after HCV and diabetes.

The situation seems similar when sleep efficacy is evaluated by the ESS questionnaire, which is used in the current study; when cirrhotic patients were compared to healthy subjects, they had severe and a higher degree of EDS \[[@ref16], [@ref17]\].

The impact of SDB on blood oxygen tension was investigated among cirrhotics in this study. There was also a significant difference between control and cirrhotic groups as regard minimum SpO~2~. Cirrhotic patients experience a larger decrease in their SpO~2~ during sleep time than healthy controls do. But there were no significant differences between control and cirrhotic groups as regard sleep efficacy and base SpO~2~ ([Table 5](#T5){ref-type="table"}).

The question arises here why SDB was studied among cirrhotics, and the answer comprises two facts. First, cirrhotics had a variable degree of SDB, as confirmed in this study and in other studies \[[@ref10], [@ref18]\], and this influence their quality of life. Obstructive sleep apnea syndrome was reported as a complication of liver cirrhosis with ascites. Patients with OSA have 4 times higher prevalence of liver cirrhosis as compared to the general population \[[@ref19]\]. Furthermore, the use of daytime sleepiness questionnaires found no differences in symptoms between patients with OSA and cirrhosis versus patients with OSA alone**.** Thus, obstructive sleep apnea should often be considered when a patient with liver cirrhosis complains of fatigue and sleep disturbances \[[@ref18]\]. An important point here is that the patients enrolled in the current study were not referred for sleep study because they were complaining. Simply, they were evaluated for research purposes, and this confirms our assumption that SDB among cirrhotics is a problem underestimated by patients, relatives, and even physicians.

Second, it is surprising to us as clinicians to know that different forms of SDB, e.g. OSA, had deleterious effects on the liver although this had been reported in the literature with controversial conclusions. As it is becoming clear that OSA is an independent risk factor of liver injury, the early detection and initiation of treatment of sleep apnea now play a pivotal role in the management of liver cirrhosis \[[@ref20], [@ref21]\]. OSA is associated with elevated alanine aminotransferase levels and a trend toward histologic evidence of progressive liver disease \[[@ref22]\]. A small sample size study of 17 patients showed improvement in executive functions after continuous positive airway pressure (CPAP) treatment of OSA, which was in turn an independent predictor of concomitant liver cirrhosis \[[@ref23]\]. An interesting study found that chronic intermittent hypoxia in mice with induced obesity is associated with liver fibrosis due to activation of pro-inflammatory pathways of liver fibrosis \[[@ref24]\].

But what is the mechanism behind the association of SDB and liver cirrhosis?

Studies have reported elimination of OSA after ascites treatment, raising the possibility of the mechanical effect of ascites on diaphragmatic movement and reduction of the lung volume as a cause of OSA. Ascites induces diaphragmatic elevation, leading to a decreased functional residual capacity, and this can induce oxygen desaturation because of ventilation perfusion mismatch \[[@ref25]\]. The occurrence of edema in the pharyngeal and laryngeal soft tissues in these patients could increase the collapsibility of the upper airways and is considered another possibility for occurrence of OSA among cirrhotic patients \[[@ref26], [@ref27]\].

Hypocapnia secondary to hormonal and chemical changes in liver cirrhosis may cause sleep apnea, although this is considered controversial \[[@ref28]\]. An early study reported that patients with cirrhosis had markedly elevated melatonin levels during daytime hours. In addition, the time of onset of melatonin increase and the time at which melatonin levels peaked were consistently and significantly delayed in these patients \[[@ref29]\].

This study has limitations. First, the number of patients recruited is small. Second, the study lacks both in depth analysis of the prior episodes of HE and testing for minimal HE, because HE by itself is associated with sleep disorders among cirrhotics \[[@ref14]\] and one study concluded that prior HE may synergize with OSA in worsening sleep patterns in cirrhotics \[[@ref18]\].

In conclusion, it seems that post-viral cirrhotic patients had a wide range of sleep-disordered breathing with variable severity detected by both questionnaires and polysomnography. This may be due to complex interactions between mechanical factors, hemodynamic factors, and vasoactive influences. Additional large studies are needed to confirm these findings in different causes of liver cirrhosis and better elucidate the mechanism underlying this relationship.
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